Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
1.
J Am Heart Assoc ; 11(24): e8067, 2022 12 20.
Artículo en Inglés | MEDLINE | ID: mdl-36533625

RESUMEN

Background Since July 2018, numerous lots of valsartan have been found to be contaminated with N-nitrosodimethylamine (NDMA). We aimed to assess the association between exposure to valsartan products contaminated with NDMA and the risk of cancer. Methods and Results This study was based on data from the Système National des Données de Santé, which is a national database that includes all French residents' health-related expenses. The target population was consumers of valsartan between January 1, 2013 and December 31, 2017, aged between 40 and 80 years old. The association of exposure to contaminated valsartan with the occurrence of any malignancy and cancer by location was evaluated by fitting Cox proportional hazards models weighted by the inverse probability of treatment. A total of 1.4 million subjects without any history of cancer were included. A total of 986 126 and 670 388 patients were exposed to NDMA-contaminated and uncontaminated valsartan, respectively. The use of the NDMA-contaminated valsartan did not increase the overall risk of cancer (adjusted hazard ratio [aHR], 0.99 [95% CI, 0.98-1.0]). However, exposed patients had a higher risk of liver cancer (aHR, 1.12 [95% CI, 1.04-1.22]) and melanoma (aHR, 1.10 [95% CI, 1.03-1.18]). We estimated a mean of 3.7 and 5.8 extra cases per year per 100 000 person-years of liver cancer and melanoma, respectively. Conclusions Our study was the largest to date to examine cancer risks associated with exposure to NDMA-contaminated valsartan. Our findings suggest a slight increased risk of liver cancer and melanoma in patients exposed to NDMA in regularly taken medications.


Asunto(s)
Neoplasias Hepáticas , Melanoma , Humanos , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Valsartán/efectos adversos , Dimetilnitrosamina/efectos adversos , Contaminación de Medicamentos , Neoplasias Hepáticas/inducido químicamente , Neoplasias Hepáticas/epidemiología
2.
Br J Cancer ; 125(6): 826-838, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34316020

RESUMEN

BACKGROUND: Cancer stem cells (CSCs) are related to the patient's prognosis, recurrence and therapy resistance in oesophageal squamous cell carcinoma (ESCC). Although increasing evidence suggests that aspirin (acetylsalicylic acid, ASA) could lower the incidence and improve the prognosis of ESCC, the mechanism(s) remains to be fully understood. METHODS: We investigated the role of ASA in chemotherapy/chemoprevention in human ESCC cell lines and an N-nitrosomethylbenzylamine-induced rat ESCC carcinogenesis model. The effects of combined treatment with ASA/cisplatin on ESCC cell lines were examined in vitro and in vivo. Sphere-forming cells enriched with putative CSCs (pCSCs) were used to investigate the effect of ASA in CSCs. Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) was performed to determine the alterations in chromatin accessibility caused by ASA in ESCC cells. RESULTS: ASA inhibits the CSC properties and enhances cisplatin treatment in human ESCC cells. ATAC-seq indicates that ASA treatment results in remarkable epigenetic alterations on chromatin in ESCC cells, especially their pCSCs, through the modification of histone acetylation levels. The epigenetic changes activate Bim expression and promote cell death in CSCs of ESCC. Furthermore, ASA prevents the carcinogenesis of NMBzA-induced ESCC in the rat model. CONCLUSIONS: ASA could be a potential chemotherapeutic adjuvant and chemopreventive drug for ESCC treatment.


Asunto(s)
Aspirina/administración & dosificación , Cisplatino/administración & dosificación , Neoplasias Esofágicas/tratamiento farmacológico , Carcinoma de Células Escamosas de Esófago/tratamiento farmacológico , Células Madre Neoplásicas/efectos de los fármacos , Animales , Aspirina/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Cisplatino/farmacología , Dimetilnitrosamina/efectos adversos , Dimetilnitrosamina/análogos & derivados , Sinergismo Farmacológico , Epigénesis Genética/efectos de los fármacos , Neoplasias Esofágicas/inducido químicamente , Neoplasias Esofágicas/genética , Carcinoma de Células Escamosas de Esófago/inducido químicamente , Carcinoma de Células Escamosas de Esófago/genética , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , Ratones , Ratas , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Environ Mol Mutagen ; 62(5): 288-292, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33963777

RESUMEN

Exposure to N-nitrosodimethylamine (NDMA) has recently been linked to a childhood cancer cluster in Wilmington, MA, which is home to the Olin Chemical Superfund Site. When it was discovered in the 1990's that 22 children in a town of under 22,000 people got cancer, the community took action and pressed for an investigation into the possibility that chemicals from the Olin Chemical site had contaminated their water. This led to the eventual discovery that NDMA was present in the town water supply. NDMA has long been known for its potent carcinogenicity in animal models, and so the community pointed to NDMA as a possible cause. This led to an investigation by the Massachusetts Department of Public Health, which, in 2021, released its findings showing an association between NDMA exposure in utero and childhood cancer. The mission of the NIEHS Superfund Research Program is to protect human health from hazardous substances. In 2017, in response to community concerns, a team at MIT created the MIT Superfund Research Program Center with a focus on research related to NDMA. Just 1 week prior to the release of the Department of Public Health study, the MIT Superfund Research Program Center published a manuscript in Cell Reports that identifies the Alkyladenine DNA glycosylase (AAG) as a possible genetic susceptibility factor. This commentary provides an author's perspective on the context and implications of this and related research.


Asunto(s)
Dimetilnitrosamina/efectos adversos , Exposición Materna/efectos adversos , Neoplasias/epidemiología , Efectos Tardíos de la Exposición Prenatal/epidemiología , Contaminantes Químicos del Agua/efectos adversos , Niño , Femenino , Humanos , Massachusetts/epidemiología , Neoplasias/inducido químicamente , Neoplasias/patología , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/patología
4.
Nutrients ; 14(1)2021 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-35010924

RESUMEN

Non-alcoholic steatohepatitis (NASH) can cause liver cirrhosis and hepatocellular carcinoma (HCC), with cases increasing worldwide. To reduce the incidence of liver cirrhosis and HCC, NASH is targeted for the development of treatments, along with viral hepatitis and alcoholic hepatitis. Lactoferrin (LF) has antioxidant, anti-cancer, and anti-inflammatory activities. However, whether LF affects NASH and fibrosis remains unelucidated. We aimed to clarify the chemopreventive effect of LF on NASH progression. We used a NASH model with metabolic syndrome established using connexin 32 (Cx32) dominant negative transgenic (Cx32ΔTg) rats. Cx32ΔTg rats (7 weeks old) were fed a high-fat diet and intraperitoneally injected with dimethylnitrosamine (DMN). Rats were divided into three groups for LF treatment at 0, 100, or 500 mg/kg/day for 17 weeks. Lactoferrin significantly protected steatosis and lobular inflammation in Cx32ΔTg rat livers and attenuated bridging fibrosis or liver cirrhosis induced by DMN. By quantitative RT-PCR, LF significantly down-regulated inflammatory (Tnf-α, Il-6, Il-18, and Il-1ß) and fibrosis-related (Tgf-ß1, Timp2, and Col1a1) cytokine mRNAs. Phosphorylated nuclear factor (NF)-κB protein decreased in response to LF, while phosphorylated JNK protein was unaffected. These results indicate that LF might act as a chemopreventive agent to prevent hepatic injury, inflammation, and fibrosis in NASH via NF-κB inactivation.


Asunto(s)
Lactoferrina/farmacología , Cirrosis Hepática/prevención & control , FN-kappa B/metabolismo , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Animales , Anticarcinógenos/farmacología , Carcinogénesis/efectos de los fármacos , Carcinoma Hepatocelular/tratamiento farmacológico , Conexinas/metabolismo , Citocinas/metabolismo , Dimetilnitrosamina/efectos adversos , Fibrosis/prevención & control , Lactoferrina/administración & dosificación , Hígado/lesiones , Neoplasias Hepáticas/tratamiento farmacológico , Masculino , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Ratas , Factor de Crecimiento Transformador beta1/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Proteína beta1 de Unión Comunicante
6.
Clin Transl Sci ; 13(4): 649-651, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32107850

RESUMEN

Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs. the benefits of the medication. This article comments on what is currently known about the evolving situation of elevated N-nitrosodimethylamine levels in ranitidine and the limits of the existing information to assess best practices.


Asunto(s)
Dimetilnitrosamina/efectos adversos , Contaminación de Medicamentos , Reflujo Gastroesofágico/tratamiento farmacológico , Medios de Comunicación de Masas , Ranitidina/efectos adversos , Carcinogénesis/inducido químicamente , Recall de Medicamento , Estabilidad de Medicamentos , Humanos , Difusión de la Información , Neoplasias/inducido químicamente , Neoplasias/prevención & control , Ranitidina/química , Ranitidina/normas , Estados Unidos , United States Food and Drug Administration/normas
7.
Ecotoxicol Environ Saf ; 170: 412-417, 2019 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-30550972

RESUMEN

In this study, a health risk assessment of N-nitrosodimethylamine (NDMA) in drinking water and food was conducted using disability-adjusted life years (DALYs) in major cities of China. Considering the numerous non-detected values found in drinking water samples, a zero-inflated model was employed to obtain a more precise NDMA concentration distribution function in drinking water. With exogenous chronic daily intake of 1.20 × 10-6 mg/(kg*d), the lifetime cancer risk and disability-adjusted life years of NDMA are 4.01 × 10-5 and 5.52 × 10-6 per person-year (ppy). The disease burden attributable to water sources accounts for nearly 9.94% of total exogenous intake. The contribution rate of vegetables is the largest, followed by cereals, milk products, fish and shrimp, and meat. Taking endogenous sources into consideration, the contribution rates of drinking water and food sources decrease to 0.08% and 0.69%. This study provides a scientific basis for making policy decisions on NDMA pollution management.


Asunto(s)
Dimetilnitrosamina/análisis , Agua Potable/análisis , Contaminación de Alimentos/análisis , Años de Vida Ajustados por Calidad de Vida , China , Ciudades , Dimetilnitrosamina/efectos adversos , Análisis de los Alimentos , Humanos , Modelos Teóricos , Neoplasias/inducido químicamente , Neoplasias/diagnóstico , Medición de Riesgo , Factores de Riesgo
8.
BMJ ; 362: k3851, 2018 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-30209057

RESUMEN

OBJECTIVE: To perform an expedited assessment of cancer risk associated with exposure to N-nitrosodimethylamine (NDMA) through contaminated valsartan products. DESIGN: Nationwide cohort study. SETTING: Danish health registries on individual level prescription drug use, cancer occurrence, and hospital diagnoses. PARTICIPANTS: 5150 Danish patients with no history of cancer, aged 40 years or older, and using valsartan at 1 January 2012 or initiating use between 1 January 2012 and 30 June 2017. Participants were followed from one year after cohort entry (lag time period) until experiencing a cancer outcome, death, migration, or end of study period (30 June 2018). Each participant's exposure to NDMA (ever exposure and predefined categories of cumulative valsartan exposure) was mapped out as a time varying variable while also applying a one year lag. MAIN OUTCOME MEASURES: Association between NDMA exposure and a primary composite endpoint comprising all cancers except non-melanoma skin cancer, estimated using Cox regression. In supplementary analyses, the risk of individual cancers was determined. RESULTS: The final cohort comprised 5150 people followed for a median of 4.6 years. In total, 3625 cohort participants contributed 7344 person years classified as unexposed to NDMA, and 3450 participants contributed 11 920 person years classified as ever exposed to NDMA. With 104 cancer outcomes among NDMA unexposed participants and 198 among exposed participants, the adjusted hazard ratio for overall cancer was 1.09 (95% confidence interval 0.85 to 1.41), with no evidence of a dose-response relation (P=0.70). For single cancer outcomes, increases in risk were observed for colorectal cancer (hazard ratio 1.46, 95% confidence interval 0.79 to 2.73) and for uterine cancer (1.81, 0.55 to 5.90), although with wide confidence intervals that included the null. CONCLUSIONS: The results do not imply a markedly increased short term overall risk of cancer in users of valsartan contaminated with NDMA. However, uncertainty persists about single cancer outcomes, and studies with longer follow-up are needed to assess long term cancer risk.


Asunto(s)
Dimetilnitrosamina/efectos adversos , Contaminación de Medicamentos/estadística & datos numéricos , Neoplasias/inducido químicamente , Valsartán/efectos adversos , Adulto , Anciano , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Estudios de Cohortes , Neoplasias Colorrectales/inducido químicamente , Neoplasias Colorrectales/epidemiología , Dinamarca/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Factores de Riesgo , Neoplasias Uterinas/inducido químicamente , Neoplasias Uterinas/epidemiología , Valsartán/uso terapéutico
9.
J Biomol Struct Dyn ; 35(5): 1020-1029, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26982119

RESUMEN

In our study, renal cancer is induced in rats making use of dimethylnitrosamine (DMN). G1 - Group 1 were control rats and G2 - Group 2 rats were given a single intra-peritoneal injection of DMN of 50 mg/kg body weight resulting in 100% incidences of renal tumors after 12 months. SEM and histopathology confirmed the presence of renal cancer in the DMN-treated rats. Making use of ammonium sulfate precipitation and gel filtration chromatography on Sephacryl S-100HR column, a thiol protease inhibitor was isolated from kidney of control rats known as Rat kidney Cystatin (RKC) as well as from kidney of cancerous rat called as Cancerous Rat Kidney Cystatin (CRKC). Both these inhibitors were characterized, and interestingly, it was found that CRKC showed greater anti-papain activity and also it was stable in a broad pH and temperature range thus implying that CRKC is more stable as compared to RKC. UV and fluorescence spectroscopy point out in structural difference between RKC and CRKC which was further confirmed by Circular dichroism (CD) and FTIR spectroscopy. Our study clearly showed that kidney cystatin is structurally modified in the case of renal cancer and performs its role in a more efficacious manner.


Asunto(s)
Cistatinas/química , Animales , Biomarcadores de Tumor , Biopsia , Dicroismo Circular , Cistatinas/metabolismo , Dimetilnitrosamina/efectos adversos , Concentración de Iones de Hidrógeno , Neoplasias Renales/inducido químicamente , Neoplasias Renales/diagnóstico , Neoplasias Renales/metabolismo , Neoplasias Renales/ultraestructura , Masculino , Pronóstico , Estabilidad Proteica , Ratas , Espectroscopía Infrarroja por Transformada de Fourier , Relación Estructura-Actividad , Termodinámica
10.
Mol Carcinog ; 55(11): 1867-1875, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27696538

RESUMEN

Aberrant methylation of DNA is a common event in the development of cancers, including squamous cell carcinoma (SCC) of the human esophagus. In the present study, we determined: (a) whether aberrant DNA methylation also occurs in the development of N-nitrosomethylbenzylamine (NMBA)-induced tumorigenesis in the rat esophagus, a model of human esophageal SCC; and (b) if so, whether dietary black raspberries (BRBs) are capable of preventing this aberrant DNA methylation. A diet containing 5% BRBs inhibited the development of NMBA-induced tumors in the rat esophagus. This inhibition was associated with reduced mRNA levels of the DNA methyltransferases, Dnmt1 and Dnmt3b, in both dysplastic lesions and in papillomas of the esophagus. In addition, promoter methylation of Sfrp4, a WNT pathway antagonist, was significantly reduced by the berry diet, and this was associated with decreased nuclear localization of ß-CATENIN and reduced expression of c-MYC protein in NMBA-treated esophagi. Decreased promoter methylation of Sfrp4 correlated with decreased expression of Dmnt3b and, ultimately, with increased Sfrp4 mRNA expression. This suggests that epigenetic alterations in NMBA-induced rat esophageal tumorigenesis recapitulate epigenetic events in human esophageal SCC, and that BRBs could be useful in preventing the aberrant DNA methylation involved in the development of human esophageal SCC. © 2015 Wiley Periodicals, Inc.


Asunto(s)
Carcinoma de Células Escamosas/dietoterapia , ADN (Citosina-5-)-Metiltransferasas/genética , Dimetilnitrosamina/análogos & derivados , Neoplasias Esofágicas/dietoterapia , Extractos Vegetales/administración & dosificación , Proteínas Proto-Oncogénicas/genética , Rubus/química , Animales , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/genética , ADN (Citosina-5-)-Metiltransferasa 1 , Metilación de ADN/efectos de los fármacos , Dimetilnitrosamina/efectos adversos , Epigénesis Genética/efectos de los fármacos , Neoplasias Esofágicas/inducido químicamente , Neoplasias Esofágicas/genética , Carcinoma de Células Escamosas de Esófago , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , Extractos Vegetales/farmacología , Ratas , Vía de Señalización Wnt/efectos de los fármacos , ADN Metiltransferasa 3B
11.
Sci Rep ; 6: 33593, 2016 09 20.
Artículo en Inglés | MEDLINE | ID: mdl-27646469

RESUMEN

Liver fibrosis is a wound-healing response characterized with the accumulation of extracellular matrix (ECM). And hepatic stellate cells (HSCs) are the principal cell source of ECM. NR4A2 (Nurr1) is a member of orphan nuclear receptor NR4A family and acts as transcription factor. It participates in regulating cell differentiation, proliferation and apoptosis. We previously demonstrated that NR4A2 expression in fibrotic liver reduced significantly compared with normal liver and NR4A2 knockout in HSCs promoted ECM production. In the present study we explored the role of NR4A2 on liver fibrosis. Studies in cultured HSCs demonstrated that NR4A2 over-expression suppressed the activation of HSCs, such as ECM production and invasion ability. Moreover cell cycle was arrested, cell apoptosis was promoted and cell signaling pathway was influenced. Adenovirus-mediated delivery of NR4A2 in rats ameliorated significantly dimethylnitrosamine (DMN) induced liver fibrosis. The In vivo experiments produced results consistent with in vitro experiments. Taken together these results demonstrate NR4A2 enhancement attenuates liver fibrosis via suppressing the activation of HSCs and NR4A2 may be an ideal target for anti-fibrotic therapy.


Asunto(s)
Adenoviridae/genética , Expresión Génica , Vectores Genéticos/genética , Células Estrelladas Hepáticas/metabolismo , Cirrosis Hepática/genética , Miembro 2 del Grupo A de la Subfamilia 4 de Receptores Nucleares/genética , Transducción Genética , Transporte Activo de Núcleo Celular , Animales , Apoptosis/genética , Puntos de Control del Ciclo Celular/genética , Movimiento Celular/genética , Proliferación Celular , Dimetilnitrosamina/efectos adversos , Modelos Animales de Enfermedad , Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Terapia Genética , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/patología , Cirrosis Hepática/terapia , Masculino , Proteína Quinasa 1 Activada por Mitógenos , Proteína Quinasa 3 Activada por Mitógenos , Miembro 2 del Grupo A de la Subfamilia 4 de Receptores Nucleares/metabolismo , Fosforilación , Ratas
12.
Zhonghua Liu Xing Bing Xue Za Zhi ; 37(5): 725-9, 2016 May.
Artículo en Chino | MEDLINE | ID: mdl-27188372

RESUMEN

OBJECTIVE: To analyze the relationship between N-nitrosodimethylamine(NDMA)and the risk of digestive tract cancers. METHODS: The papers about the relationship between NDMA and the risk of digestive tract cancers published from 1980 to 2012 were retrieved following databases: Chinese BioMedical Literature Database(CBM), the Chinese Journal Full-text Database(CNKI), Wanfang Database, PubMed and EBSCO. The fix and random effect model was used and statistical analyses were conducted by using RevMan 5.1 software. RESULTS: Thirteen papers were found, in which 7 about digestive tract cancers were used in this Meta analysis. The NDMA had significant positive effect on the incidence of digestive tract cancers(RR=1.12, 95% CI: 1.03-1.21). The relationship between NDMA and esophageal cancer was not significant(RR=1.18, 95%CI: 0.98-1.41)but NDMA could increase the risk of gastric cancer(RR=1.08, 95% CI: 1.00-1.18). For the subtypes of esophageal and gastric cancer, NDMA had positive relationship with esophageal squamous cell carcinoma(RR=1.72, 95% CI: 1.01-2.96), but had no significant relationship with esophageal adenocarcinoma, cardiac carcinoma and gastric adenocarcinoma. CONCLUSION: The population-based cohort studies have showed that the NDMA could significantly increase the risk of digestive tract cancers, but the effects differed with subtypes of esophageal and gastric cancer. However, it is necessary to collect more evidence due to the limited studies and obvious differences in the study design, sampling and exposure measurement of these cohort studies.


Asunto(s)
Pueblo Asiatico/estadística & datos numéricos , Neoplasias del Sistema Digestivo/inducido químicamente , Dimetilnitrosamina/efectos adversos , Neoplasias Gastrointestinales/inducido químicamente , Adenocarcinoma , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/epidemiología , China/epidemiología , Estudios de Cohortes , Neoplasias del Sistema Digestivo/etiología , Dimetilnitrosamina/administración & dosificación , Neoplasias Esofágicas/inducido químicamente , Neoplasias Esofágicas/epidemiología , Carcinoma de Células Escamosas de Esófago , Neoplasias Gastrointestinales/epidemiología , Humanos , Incidencia , Vigilancia de la Población , Medición de Riesgo , Factores de Riesgo , Neoplasias Gástricas/inducido químicamente
13.
PLoS Negl Trop Dis ; 9(8): e0004008, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26313366

RESUMEN

BACKGROUND: Clonorchis sinensis is a group-I bio-carcinogen for cholangiocarcinoma (CCA). Although the epidemiological evidence links clonorchiasis and CCA, the underlying molecular mechanism involved in this process is poorly understood. In the present study, we investigated expression of oncogenes and tumor suppressors, including PSMD10, CDK4, p53 and RB in C. sinensis induced hamster CCA model. METHODS: Different histochemical/immunohistochemical techniques were performed to detect CCA in 4 groups of hamsters: uninfected control (Ctrl.), infected with C. sinensis (Cs), ingested N-nitrosodimethylamine (NDMA), and both Cs infected and NDMA introduced (Cs+NDMA). The liver tissues from all groups were analyzed for gene/protein expressions by quantitative PCR (qPCR) and western blotting. PRINCIPAL FINDINGS: CCA was observed in all hamsters of Cs+NDMA group with well, moderate, and poorly differentiated types measured in 21.8% ± 1.5%, 13.3% ± 1.3%, and 10.8% ± 1.3% of total tissue section areas respectively. All CCA differentiations progressed in a time dependent manner, starting from the 8th week of infection. CCA stroma was characterized with increased collagen type I, mucin, and proliferative cell nuclear antigen (PCNA). The qPCR analysis showed PSMD10, CDK4 and p16INK4 were over-expressed, whereas p53 was under-expressed in the Cs+NDMA group. We observed no change in RB1 at mRNA level but found significant down-regulation of RB protein. The apoptosis related genes, BAX and caspase 9 were found downregulated in the CCA tissue. Gene/protein expressions were matched well with the pathological changes of different groups except the NDMA group. Though the hamsters in the NDMA group showed no marked pathological lesions, we observed over-expression of Akt/PKB and p53 genes proposing molecular interplay in this group which might be related to the CCA initiation in this animal model. CONCLUSIONS/SIGNIFICANCE: The present findings suggest that oncogenes, PSMD10 and CDK4, and tumor suppressors, p53 and RB, are involved in the carcinogenesis process of C. sinensis induced CCA in hamsters.


Asunto(s)
Colangiocarcinoma/metabolismo , Clonorquiasis/metabolismo , Clonorchis sinensis/fisiología , Quinasa 4 Dependiente de la Ciclina/metabolismo , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteína de Retinoblastoma/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Animales , Colangiocarcinoma/inducido químicamente , Colangiocarcinoma/genética , Colangiocarcinoma/parasitología , Clonorquiasis/genética , Clonorquiasis/parasitología , Cricetinae , Quinasa 4 Dependiente de la Ciclina/genética , Dimetilnitrosamina/efectos adversos , Modelos Animales de Enfermedad , Humanos , Masculino , Mesocricetus , Complejo de la Endopetidasa Proteasomal/genética , Proteína de Retinoblastoma/genética , Proteína p53 Supresora de Tumor/genética
14.
PLoS One ; 10(7): e0131560, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26147856

RESUMEN

Rhizoma Paridis Saponins (RPS), a natural compound purified from Rhizoma Paridis, has been found to inhibit cancer growth in vitro and in animal models of cancer. However, its effects on esophageal cancer remain unexplored. The purpose of this study was to investigate the effects of RPS on tumor growth in a rat model of esophageal cancer and the molecular mechanism underlying the effects. A rat model of esophageal cancer was established by subcutaneous injection of N-nitrosomethylbenzylamine (NMBA, 1 mg/kg) for 10 weeks. RPS (350 mg/kg or 100 mg/kg) was administered by oral gavage once daily for 24 weeks starting at the first NMBA injection. RPS significantly reduced the size and number of tumors in the esophagus of rats exposed to NMBA and inhibited the viability, migration, and invasion of esophageal cancer cells EC9706 and KYSE150 in a dose dependent manner (all P < 0.01). Flow cytometry revealed that RPS induced apoptosis and cell cycle G2/M arrest in the esophageal cancer cells. The expression of cyclooxygenases-2 (COX-2) and Cyclin D1 in rat esophageal tissues and the esophageal cancer cells were also significantly reduced by RPS (all P < 0.01). Consistently, RPS also significantly decreased the release of prostaglandin E2, a downstream molecule of COX-2, in a dose-dependent manner (P < 0.01). Our study suggests that RPS inhibit esophageal cancer development by promoting apoptosis and cell cycle arrest and inhibiting the COX-2 pathway. RPS might be a promising therapeutic agent for esophageal cancer.


Asunto(s)
Ciclooxigenasa 2/metabolismo , Dimetilnitrosamina/análogos & derivados , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/metabolismo , Extractos Vegetales/farmacología , Rizoma/química , Saponinas/farmacología , Animales , Puntos de Control del Ciclo Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ciclina D1/metabolismo , Dimetilnitrosamina/efectos adversos , Dinoprostona/metabolismo , Neoplasias Esofágicas/inducido químicamente , Neoplasias Esofágicas/patología , Esófago/efectos de los fármacos , Esófago/metabolismo , Esófago/patología , Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos , Masculino , Extractos Vegetales/química , Ratas , Ratas Endogámicas F344 , Saponinas/química
15.
Food Funct ; 5(11): 2883-91, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25183344

RESUMEN

Garcinol, a polyisoprenylated benzophenone derivative, mainly isolated from Garcinia indica fruit rind, has been suggested to exhibit many biological benefits including antioxidative, anti-inflammatory, and anti-tumor activities. The aim of this study is to evaluate the protective effects of garcinol on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. The administration of DMN for six consecutive weeks resulted in the decrease of body weights, the elevation of serum aminotransferases, as well as histological lesions in livers. However, oral administration of garcinol remarkably inhibited the elevation of aspartate transaminase (AST) and relieved liver damage induced by DMN. Furthermore, our results revealed that garcinol not only effectively reduced the accumulation of extracellular matrix (ECM) components but also inhibited the expression of α-smooth muscle actin (α-SMA) in livers. The expression of transforming growth factor-ß1 (TGF-ß1) and the phosphorylation of Smad 2 and Smad 3 were also suppressed by garcinol supplementation. In conclusion, our current study suggested that garcinol exerted hepatoprotective and anti-fibrotic effects against DMN-induced liver injury in rats.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Dimetilnitrosamina/efectos adversos , Cirrosis Hepática/tratamiento farmacológico , Terpenos/farmacología , Animales , Aspartato Aminotransferasas/metabolismo , Frutas/química , Garcinia/química , Hígado/efectos de los fármacos , Hígado/metabolismo , Cirrosis Hepática/inducido químicamente , Masculino , Fosforilación , Ratas , Ratas Sprague-Dawley , Proteína Smad2/genética , Proteína Smad2/metabolismo , Proteína smad3/genética , Proteína smad3/metabolismo , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/metabolismo
16.
Parasitol Res ; 113(3): 829-35, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24318666

RESUMEN

Worldwide, the highest incidence of cholangiocarcinoma (CCA) is found in northeast Thailand, the endemic area of Opisthorchis viverrini infection. Cumulated clinical data revealed that the majority of CCA patients are men. However, many other types of cancers are more commonly found in women. In this study, we investigated the sex differences in the development of CCA, induced by O. viverrini infection and N-nitrosodimethylamine administration, in Syrian hamsters. Histopathology, liver function tests, and fecal egg counts were analyzed. The results showed that there are no sex differences in hamsters responses to O. viverrini infection and no prevalence of CCA development. Even though serum ALT level in O. viverrini-infected or CCA hamsters was significantly increased in female compared to male (p < 0.05) and uninfected control (p < 0.05), our results may imply that the higher prevalence of opisthorchiasis and CCA in men than in women in northeast Thailand may depend on behaviors of an individual exposed to risk factors rather than gender difference.


Asunto(s)
Neoplasias de los Conductos Biliares/patología , Colangiocarcinoma/patología , Opistorquiasis/patología , Factores Sexuales , Animales , Neoplasias de los Conductos Biliares/inducido químicamente , Neoplasias de los Conductos Biliares/parasitología , Conductos Biliares Intrahepáticos/patología , Colangiocarcinoma/inducido químicamente , Colangiocarcinoma/parasitología , Cricetinae , Dimetilnitrosamina/efectos adversos , Modelos Animales de Enfermedad , Femenino , Humanos , Hígado/parasitología , Hígado/patología , Pruebas de Función Hepática , Masculino , Mesocricetus , Opistorquiasis/complicaciones , Opisthorchis , Recuento de Huevos de Parásitos , Tailandia
17.
Br J Nutr ; 111(6): 1109-17, 2014 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-24160559

RESUMEN

Several N-nitroso compounds (NOC) have been shown to be carcinogenic in a variety of laboratory animals, but evidence of their carcinogenicity in humans is lacking. We aimed to examine the association between NOC intake and colorectal cancer (CRC) risk and possible effect modification by vitamins C and E and protein in a large case-control study carried out in Newfoundland and Labrador and Ontario, Canada. A total of 1760 case patients with pathologically confirmed adenocarcinoma and 2481 population controls were asked to complete a self-administered FFQ to evaluate their dietary intakes 1 year before diagnosis (for cases) or interview (for controls). Adjusted OR and 95 % CI were calculated across the quintiles of NOC (measured by N-nitrosodimethylamine (NDMA)) intake and relevant food items using unconditional logistic regression. NDMA intake was found to be associated with a higher risk of CRC (highest v. lowest quintiles: OR 1·42, 95 % CI 1·03, 1·96; P for trend = 0·005), specifically for rectal carcinoma (OR 1·61, 95 % CI 1·11, 2·35; P for trend = 0·01). CRC risk also increased with the consumption of NDMA-containing meats when the highest tertile was compared with the lowest tertile (OR 1·47, 95 % CI 1·03, 2·10; P for trend = 0·20). There was evidence of effect modification between dietary vitamin E and NDMA. Individuals with high NDMA and low vitamin E intakes had a significantly increased risk than those with both low NDMA and low vitamin E intakes (OR 3·01, 95 % CI 1·43, 6·51; P for interaction = 0·017). The present results support the hypothesis that NOC intake may be positively associated with CRC risk in humans. Vitamin E, which inhibits nitrosation, could modify the effect of NDMA on CRC risk.


Asunto(s)
Neoplasias Colorrectales/inducido químicamente , Dieta , Compuestos Nitrosos/administración & dosificación , Compuestos Nitrosos/efectos adversos , Adenocarcinoma/inducido químicamente , Adenocarcinoma/prevención & control , Adulto , Anciano , Ácido Ascórbico/administración & dosificación , Estudios de Casos y Controles , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/prevención & control , Proteínas en la Dieta/administración & dosificación , Dimetilnitrosamina/administración & dosificación , Dimetilnitrosamina/efectos adversos , Femenino , Humanos , Modelos Logísticos , Masculino , Carne , Persona de Mediana Edad , Terranova y Labrador/epidemiología , Ontario/epidemiología , Neoplasias del Recto/inducido químicamente , Neoplasias del Recto/prevención & control , Factores de Riesgo , Encuestas y Cuestionarios , Vitamina E/administración & dosificación
18.
Food Chem Toxicol ; 56: 231-9, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23485615

RESUMEN

The purpose of this study was to investigate the anti-fibrotic effects of the aqueous extract of the Platycodi Radix root (Changkil: CK) on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. DMN treatment for 4 weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and collagen content. CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content. CK also inhibited DMN-induced reductions in rat body and liver weights. Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein. DMN-induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment. Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells. These results demonstrated that CK attenuates DMN-induced liver fibrosis through the activation of Nrf2-mediated antioxidant enzymes.


Asunto(s)
Antioxidantes/farmacología , Dimetilnitrosamina/efectos adversos , Cirrosis Hepática/patología , Extractos Vegetales/farmacología , Actinas/metabolismo , Alanina Transaminasa/sangre , Animales , Aspartato Aminotransferasas/sangre , Colágeno Tipo I/metabolismo , Ciclooxigenasa 2/metabolismo , Glutamato-Cisteína Ligasa/metabolismo , Glutatión Transferasa/metabolismo , Hemo Oxigenasa (Desciclizante)/metabolismo , Células Hep G2 , Humanos , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/tratamiento farmacológico , Masculino , Malondialdehído/sangre , Metaloproteinasa 13 de la Matriz/metabolismo , NAD(P)H Deshidrogenasa (Quinona)/metabolismo , Factor 2 Relacionado con NF-E2/metabolismo , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Raíces de Plantas/química , Platycodon , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
19.
PLoS One ; 8(1): e53988, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23335984

RESUMEN

BACKGROUND: Graptopetalum paraguayense (GP) is a folk herbal medicine with hepatoprotective effects that is used in Taiwan. The aim of this study was to evaluate the hepatoprotective and antifibrotic effects of GP on experimental hepatic fibrosis in both dimethylnitrosamine (DMN)- and carbon tetrachloride (CCl(4))-induced liver injury rats. METHODS: Hepatic fibrosis-induced rats were fed with the methanolic extract of GP (MGP) by oral administration every day. Immunohistochemistry, biochemical assays, and Western blot analysis were performed. The effects of MGP on the expression of fibrotic markers and cytokines in the primary cultured hepatic stellate cells (HSCs) and Kupffer cells, respectively, were evaluated. RESULTS: Oral administration of MGP significantly alleviated DMN- or CCl(4)-induced liver inflammation and fibrosis. High levels of alanine transaminase, aspartate transaminase, bilirubin, prothrombin activity and mortality rates also decreased in rats treated with MGP. There were significantly decreased hydroxyproline levels in therapeutic rats compared with those of the liver-damaged rats. Collagen I and alpha smooth muscle actin (α-SMA) expression were all reduced by incubation with MGP in primary cultured rat HSCs. Furthermore, MGP induced apoptotic cell death in activated HSCs. MGP also suppressed lipopolysaccharide-stimulated rat Kupffer cell activation by decreasing nitric oxide, tumor necrosis factor-α and interleukin-6 production, and increasing interleukin-10 expression. CONCLUSIONS: The results show that the administration of MGP attenuated toxin-induced hepatic damage and fibrosis in vivo and inhibited HSC and Kupffer cell activation in vitro, suggesting that MGP might be a promising complementary or alternative therapeutic agent for liver inflammation and fibrosis.


Asunto(s)
Helechos/química , Células Estrelladas Hepáticas/efectos de los fármacos , Células Estrelladas Hepáticas/metabolismo , Macrófagos del Hígado/efectos de los fármacos , Macrófagos del Hígado/metabolismo , Cirrosis Hepática/metabolismo , Extractos Vegetales/farmacología , Animales , Apoptosis/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Citocinas/biosíntesis , Dimetilnitrosamina/efectos adversos , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/farmacología , Inflamación/metabolismo , Inflamación/patología , Hígado/efectos de los fármacos , Hígado/patología , Cirrosis Hepática/sangre , Cirrosis Hepática/tratamiento farmacológico , Masculino , Tamaño de los Órganos/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Ratas , Bazo/efectos de los fármacos
20.
Am J Clin Nutr ; 97(1): 135-46, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23193003

RESUMEN

BACKGROUND: Dietary N-nitroso compounds and endogenous nitrosation are important carcinogenic factors, but human evidence of their role is scarce for esophageal cancer and inconsistent for gastric cancer. OBJECTIVE: We studied the relation between risks of esophageal and gastric cancer subtypes and dietary intake of N-nitrosodimethylamine, heme iron, nitrite, and nitrate in the Netherlands Cohort Study. DESIGN: A total of 120,852 men and women aged 55-69 y were recruited in 1986, and diet, based on a 150-item food-frequency questionnaire, and other risk factors were assessed. The cohort was followed for 16.3 y, and 110 esophageal squamous cell carcinoma (ESCC), 151 esophageal adenocarcinoma, 166 gastric cardia adenocarcinoma, and 497 gastric noncardia adenocarcinoma (GNCA) cases were analyzed along with 4032 subcohort members in a case-cohort analysis. RESULTS: Positive associations were observed between N-nitrosodimethylamine intake and ESCC risk (HR for 0.1-µg/d increase in intake: 1.15; 95% CI: 1.05, 1.25; P-trend = 0.01 based on tertiles of intake) and GNCA risk (1.06; 95% CI: 1.01, 1.10; P-trend = 0.09) in men. ESCC risk was associated with nitrite intake (HR for 0.1-mg/d increase: 1.19; 95% CI: 1.05, 1.36; P-trend = 0.06) and heme-iron intake (HR for 1-mg/d increase: 1.83; 95% CI: 0.98, 3.39; P-trend = 0.03). Among women, exposure levels were lower, and we found no convincing positive associations. CONCLUSION: These results suggest that N-nitroso compounds may influence the risk of ESCC in men, but there are no clear associations for other esophageal and gastric subtypes.


Asunto(s)
Dimetilnitrosamina/efectos adversos , Neoplasias Esofágicas/patología , Nitrosación , Neoplasias Gástricas/patología , Anciano , Ácido Ascórbico/administración & dosificación , Clorofila/administración & dosificación , Dieta , Neoplasias Esofágicas/etiología , Femenino , Estudios de Seguimiento , Humanos , Hierro de la Dieta/efectos adversos , Modelos Lineales , Masculino , Persona de Mediana Edad , Análisis Multivariante , Países Bajos , Nitratos/efectos adversos , Nitritos/efectos adversos , Estudios Prospectivos , Medición de Riesgo , Factores de Riesgo , Neoplasias Gástricas/etiología , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA